No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC By Ogkologos - March 3, 2026 371 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SONIA study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Can Immunotherapy Succeed in Glioblastoma? May 24, 2018 Mississippi Teen Uses Make-A-Wish Grant To Feed Homeless In His Community November 13, 2021 Immunotherapy Plus Chemotherapy Helps People With Advanced Nasopharyngeal Cancer: The ASCO... April 18, 2022 A radical project: video game design meets cancer research December 1, 2022 Load more HOT NEWS Sevabertinib Shows Antitumour Activity in Patients with Locally Advanced or Metastatic... What Are Drug Shortages and How Can They Impact Care for... FDA Grants Regular Approval to Pembrolizumab and Lenvatinib for Advanced Endometrial... Venetoclax-Obinutuzumab With or Without Ibrutinib Is Superior to Chemoimmunotherapy in First-Line...
